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Abstract
In the past decade, an emerging process named “autophagy” has generated
intense interest in many chronic lung diseases. Tissue remodeling and fibrosis
is a common feature of many airway diseases, and current therapies do not
prevent or reverse these structural changes. Autophagy has evolved as a
conserved process for bulk degradation and recycling of cytoplasmic
components to maintain basal cellular homeostasis and healthy organelle
populations in the cell. Furthermore, autophagy serves as a cell survival
mechanism and can also be induced by chemical and physical stress to the
cell. Accumulating evidence demonstrates that autophagy plays an essential
role in vital cellular processes, including tissue remodeling. This review will
discuss some of the recent advancements made in understanding the role of
this fundamental process in airway fibrosis with emphasis on airway
remodeling, and how autophagy can be exploited as a target for airway
remodeling in asthma and chronic obstructive pulmonary disease.
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Introduction

Evidence of autophagy in asthma

Autophagy is an evolutionarily conserved pathway for the turnover of organelles and proteins by lysosomal-dependent processing1.
During autophagy, newly formed double-membrane structures,
called autophagosomes, encapsulate cytoplasmic material, such as
dysfunctional or damaged organelles or proteins. The autophagosomes then fuse with lysosomes, thus delivering the sequestered
cargo for lysosomal-dependent degradation2, as described in
Figure 1. In the last decade, autophagy has emerged as a fundamental process involved in tissue and cellular homeostasis, and thus
has been implicated in maintaining basal physiologic (healthy) and
adaptive pathophysiologic responses (disease)2–4. There is increasing evidence to suggest that autophagy can impact the pathogenesis and/or progression of many human diseases2,4,5, including
neurodegenerative diseases6, cancer7, heart diseases8,9 and immune
disorders (reviewed in 3,10).

Asthma is a chronic inflammatory disease of the lungs, characterized by airway inflammation, airway hyperresponsiveness
and tissue remodeling. It affects more than 300 million people
worldwide and this number is estimated to escalate to 400 million
by 202513.

Fibrotic airway remodeling remains a key pathological feature
correlating with a decline in lung function and disease progression
in both asthma and chronic obstructive pulmonary disease (COPD)
patients11,12. While there is no treatment for preventing development
of airway remodeling, cell fate phenomena, such as autophagy,
have been shown to play a role in asthma and COPD pathogenesis.
Here, we review the progress in understanding how autophagy can
contribute to airway fibrosis and the emerging strategies to target
this process for therapeutic benefit.

The role of autophagy in pulmonary diseases has gained attention
in the past decade, but only very few studies have described the
role of autophagy in asthma. One of the very first studies that
described a direct role between asthma and autophagy revealed the
association of the ATG5 gene in the pathogenesis of asthma14. This
study found a genetic association in 1338 adult patients with asthma
and the expression of the autophagy gene ATG5. ATG5 encodes
the ATG5 protein of 276 amino acids. During autophagy, the
ATG5 protein interacts with ATG12 and ATG16 to form a ATG12ATG5-ATG16 complex. This complex is associated with autophagosomal membrane elongation by interaction with ATG3, leading to
ATG8-phosphatidyl ethanolamine formation15. This association
was further validated in another study with 312 asthmatic and 246
control children, which showed that genetic variants in ATG5 are
associated with pathogenesis of childhood asthma16,17. Furthermore,
a study by Poon et al. revealed the role of ATG5 in adult asthma,
and also found an increased number of autophagosomes in fibroblast and epithelial cells from severe asthmatics when compared to
healthy volunteers15. Recent studies show that there is emerging

Figure 1. Pictorial representation of the autophagy pathway. The autophagy pathway proceeds through several phases, including
initiation (formation of a preautophagosomal structure leading to an isolation membrane, or phagophore), vesicle elongation, autophagosome
maturation and cargo sequestration, and autophagosome–lysosome fusion. In the final stage, autophagosomal contents are degraded by
lysosomal acid hydrolases and the contents of the autolysosome are released for metabolic recycling.
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evidence for the role of autophagy in both eosinophilic18 and
neutrophilic asthma19, and convey its link to severe asthma and
fibrotic tissue remodeling.
A recent study by Ban et al. investigated the role of autophagy in
sputum granulocytes, peripheral blood cells and peripheral blood
eosinophils of severe and non-severe asthmatics20. They found
increased autophagy in the immune cells from the severe asthmatics when compared to non-severe and healthy controls. This clearly
indicates that induction of autophagy in immune cells is associated
with severe asthma. By contrast, a study conducted by Akbari’s
group reveals the induction of neutrophilic airway inflammation
and hyperreactivity on deletion of CD11 cell specific ATG5 mice.
In addition, in this study augmented neutrophilic inflammation in
Atg5(-/-) mice is IL-17A driven and glucocorticoid resistant21.
In our own hands, we have found increased signatures of key
autophagy genes in the lungs of asthmatic patients when compared with non-asthmatics, suggesting that basal autophagy is
higher in asthma (unpublished data). Furthermore, we also found
increased expression of autophagy proteins in the lung tissue
obtained from chronic mouse model of HDM-induced asthma and
this expression was found to correlate with pro-fibrotic signaling (Smad) and extracellular matrix protein (collagen) in the lung
(unpublished data).
These data suggest that autophagy and airway fibrosis occur
together with allergic insult, and act as a key driver for airway
remodeling in allergic asthma. The current literature clearly indicates that the autophagy-phenomenon may be a crucial driver in
the pathogenesis of asthma, particularly in severe forms of the
disease, with an unknown underlying mechanism. The therapeutic modulation of autophagy with novel inhibitors may lead to the
development of a new class of drugs for severe asthma.

Evidence of autophagy in COPD
COPD is a progressive lung disease characterized by accelerated
decline in lung function over time. Its most common pathological feature includes emphysema and chronic bronchitis. Airway
obstruction in COPD in associated with formation of peribronchial fibrosis, increased wall thickness and excess mucus secretion, especially in the smaller airways22. Exposure to cigarette
smoke is one major cause of COPD; however only 25% of smokers develop COPD, which suggests the existence of numerous
other factors contributing to COPD (such as genetic predisposition
and oxidative stress)23,24. The role of autophagy in COPD seems
to be more complex than anticipated, as some studies showed
its impairment25–27, while others suggest it facilitates disease
pathogenesis28–31. More recently, the role of selective autophagy
(such as mitophagy, ciliophagy and xenophagy) in COPD
pathology has been proposed31.
The very first demonstration of autophagy in COPD was shown
by Chen et al., where authors found increased autophagy markers
in the lungs of COPD patients28. The authors also found a similar expression of elevated autophagy markers at various stages of

the disease. This suggests that altered autophagy could be a key
regulator in the pathogenesis and progression of COPD. The same
study also showed that the autophagy marker LC3II/LC3I was
significantly increased in lungs from patients with α-1 anti-trypsin
deficiency when compared with non-COPD donors28. In addition, many other studies have shown the increased expression
of autophagy markers both in vitro and in vivo when exposed to
cigarette smoke extract16,28,29,32, which explains increased loss of
alveolar epithelial cells as seen in emphysema.
Moreover, to investigate the role of autophagy in chronic bronchitis, Lam and colleagues demonstrated that induction of autophagy
leads to shortening of cilia in mouse tracheal epithelial cells
exposed to cigarette smoke30. They further found that autophagy
gene deficient mice (Becn1+/- or Map1lc3B-/-) were resistant to
the shortening of cilia in tracheal epithelial cells when exposed to
cigarette smoke, demonstrating a direct role of autophagy in this
process30. Recent studies have demonstrated that selective
autophagy (namely mitophagy) plays an important role in regulating
mitochondrial function, which in turn has a crucial role in COPD
pathogenesis33. However, the specific role of mitophagy in tissue
injury mediated by cigarette smoke remains obscure and requires
further study31.
Overall, autophagy plays a key role in COPD pathogenesis, especially in the development of emphysema, but the underlying
mechanisms by which it promotes emphysema and bronchitis in
COPD is not clear.

Autophagy and fibrotic airway remodeling
The pathogenesis of COPD and asthma is typified by structural
changes in the lung, collectively known as airway remodeling,
which is characterized by basement membrane fibrosis, epithelial
goblet cell hyperplasia, deposition of extracellular matrix proteins
and smooth muscle hypertrophy34,35. Current therapies provide
very limited benefit on airway remodeling12,36–40, thus identifying
new drug targets that can prevent or reduce airway remodeling
in asthma and COPD is vital to reverse structural changes that
determines the underlying cause of the disease34,41. TGFβ1 is a
well-known regulator of inflammation and fibrotic remodeling in
COPD and asthma, and it is upregulated in both diseases11. TGFβ1
is the most abundant isoform of the TGF-β family and is secreted
by most immune cells, including airway epithelial, smooth muscle, fibroblast and endothelial cells. TGFβ1 acts through the
Smad dependent pathway and independent pathways, like mitogen
activated protein kinases (MAPKs) namely p38 MAPK and
c-Jun-N-terminal kinase, leading to the accumulation of extracellular matrix (ECM).
Autophagy-mediated TGFβ1-induced fibrosis plays a key role
in the pathogenesis of heart and kidney diseases42,43, and recent studies in human airway smooth muscle cells have demonstrated that
TGFβ1 induced autophagy is required for collagen and fibronectin production, while silencing of key autophagy-inducing proteins
Atg5 and Atg7 leads to reduction in pro-fibrotic signaling and ECM
protein release44,45. It is now believed that increased production
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of matrix proteins, as seen in airway remodeling, requires huge
resources of energy, which is compensated by enhanced autophagy
flux within the cell45. Our own data (unpublished) demonstrates that
there is a simultaneous induction of autophagy and pro-fibrotic signaling in human airway mouse models of allergic asthma. We propose that blockade of autophagy in the lungs can lead to reduction in
airway fibrosis, as seen in airway remodeling in asthma and COPD.
Recent observations suggest that autophagy exhibits a circadian
rhythm and this rhythmic activation of autophagy is regulated by
the transcription factor C/EBPβ46. These findings need to be further
evaluated in the context of asthma and COPD, as circadian rhythm
genes can also be a potential target to modulate autophagy46.

Kinases, such as adenosine monophosphate activated protein
kinase (AMPK) and ULK1 (mammalian orthologue of yeast protein kinase Atg1) are required for autophagy. AMPK senses nutrient deficiency and positively regulates ULK1, leading to activation
of autophagy. Moreover, it has been reported that loss of either of
these kinases results in defective autophagy (mitophagy)55. Modulating the AMPK-ULK1 pathway may be an option for treatment of
chronic airway diseases. Thus, there is a need to identify the right
autophagy mechanism in the progression and development of airway remodeling in asthma and COPD, which can become a realistic
drug target to prevent structural changes in the lung.

Conclusions and future perspectives
Therapeutic strategies: Novel autophagy modulators
The mechanistic insight of disease pathogenesis in chronic airway
diseases, such as asthma and COPD, is complex. Altered structural
changes in the lung correlates with poor lung function, severity
of disease and response to therapy in asthma and COPD. Current
therapy does not target the underlying cause/s of the disease and
does not restore the structural integrity of the airways12,36–40; therefore, novel mechanisms, such as autophagy, pose attractive therapeutic options in airway remodeling. With the emerging role of
autophagy in asthma and COPD and our increased understanding
in the disease pathogenesis, we believe that the autophagy pathway
can be exploited for therapeutic benefit. One of the exciting features
of this pathway is that it can be inhibited at several steps, including initiation and vesicle elongation, autophagosome formation
and maturation, and autophagosome lysosome fusion. Emerging
evidence suggests that autophagy inhibition at the very first step is
beneficial in an ovalbumin-induced model of asthma in mice, where
3-methyl adenine, a class III PI3K inhibitor, reduced the expression of autophagy marker LC3B with simultaneous reduction in
airway eosinophilia18. However, there is a need for more research
in exploring the role of various PI3K inhibitors in the context of
autophagy dependent-airway remodeling, using the most suitable
models of asthma and COPD, as modulation of autophagy by the
PI3K pathway can be an attractive target for both severe asthma
and COPD47–50.
Bafilomycin A1 is a late phase potent inhibitor of autophagy, which
acts through the inhibition of vacuolar type H+-ATPase that is
present on lysosomes. Inhibition of vacuolar type H+-ATPase by
bafilomycin A1 leads to acidification of lysosomes and inhibits their
fusion with autophagosomes51. Previous studies also indicate that
bafilomycin inhibits the infection and airway inflammation induced
by rhinovirus52. Chloroquine is a well know anti-malarial and
anti-rheumatoid agent, and it is also used for blocking autophagy
at a late stage by lysosomal dysfunction (lysosomal lumen
alkalizers)51. The most important shortcoming of chloroquine
is that this molecule blocks autophagy only at higher concentrations. Lys01 and Lys05 were recently developed modified versions of chloroquine, which are 10-fold more potent in autophagy
inhibition51,53,54; however these require further validation in asthma
and COPD models.

Based on the current scientific data, the autophagy pathway is
directly linked to asthma and COPD pathophysiology and may act
as a potential contributor to fibrotic airway remodeling, as described
in Figure 2. Future research should be directed towards understanding the specific pathway and the mechanism/s leading to the

Figure 2. Autophagy mediates airway remodeling. An altered
autophagy pathway is seen in response to cellular stress in asthma
and chronic obstructive pulmonary disease (allergens or smoke),
leading to activation and crosstalk between structural airway and
immune cells. This further leads to impairment of autophagy causing
degradation of intracellular constituents, providing an energy
resource for ECM protein biosynthesis, and releasing mediators
of inflammation and profibrotic signaling, which collectively lead
to airway remodeling in the lung. ECM: extracellular matrix; TGFβ:
transforming growth factor-beta.
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pathophysiological activation of autophagy in disease. Efforts
should be made in developing a modulator of autophagy as a new
therapeutic strategy for treatment of airway remodeling in asthma
and COPD. In the future, we propose to study the role of circadian
rhythm genes in the activation of the autophagy pathway and understand whether modulating circadian rhythm genes, using novel
small chemical compounds, has any therapeutic benefit in animal
models of asthma and COPD.
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Summary –
The current manuscript has reviewed the literature on relationship between autophagy and airway fibrosis
in chronic lung disease, especially asthma and COPD. This topic is of great interest and very little work
has been done to understand the underlying mechanisms. I think this article is a timely reminder and will
stimulate research into this area, which is much needed. Overall, this a well presented article but I have
some suggestions, which will enhance readability and understanding on the diseases discussed.
Major comments –
1. Before authors go into the details for role of autophagy in asthma/remodeling, I think they need to
add a separate section on airway remodeling and autophagy first.
2. Please list the airway remodeling changes described in asthma so far and then discuss which
might be related to autophagy.
3. I think authors need to add a reference if there is any work done on fibroblast populations in
asthma to make the case for fibrosis or suggest as potential future work.
4. Similar changes I think need to be made for the COPD section, especially listing airway remodeling
changes described so far, for example Rbm fragmentation, vascularity, epithelial mesenchymal
transition (EMT) etc.
5. Authors stated in the evidence for autophagy in COPD section that major features are emphysema
and chronic bronchitis. I think it is very important to describe small airway destructive pathology in
COPD. The classic fixed airflow obstruction described in COPD comes from the small airways.
These airways are destroyed by up to nearly 40% well before the diagnosis of COPD. So damage
starts quite early on and it is this site where fibrosis really occurs and EMT is central to this. Airway
disease is the primary phenomenon in COPD.
6. EGFR has also been regarded as one of the important drivers of airway remodeling in asthma and
COPD, that needs to be discussed.
Is the topic of the review discussed comprehensively in the context of the current literature?
Yes
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Yes
Are all factual statements correct and adequately supported by citations?
Yes
Is the review written in accessible language?
Yes
Are the conclusions drawn appropriate in the context of the current research literature?
Yes
Competing Interests: No competing interests were disclosed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Referee Report 02 May 2017

doi:10.5256/f1000research.12123.r22182
Kimberley C.W. Wang
Telethon Kids Institute, Subiaco, WA, Australia
Summary:
This review clearly demonstrates the need for more studies investigating the role of autophagy in
respiratory disease. It is good that the authors added some unpublished data into the review article as
support of evidence.

Major comments:
1. Figure 2 can be improved. Eg: at the arrow between Autophagy and Cell Growth/ECM release, the
authors can add the words increase energy resource so the readers understand the association
between Autophagy and Cell Growth/ECM release. Authors should consider adding ‘Genetics’ into
the figure. The authors could add ‘circadian rhythm’ into the figure with a ‘?’ to show that it is a
factor for further investigation.
2. For the collectively structural changes of airway remodeling, please include smooth muscle
hyperplasia (James et al. 2012; Am J Respir Crit Care Med).
3. In the autophagy and fibrotic airway remodelling section, the paragraphs could be rearranged. Eg
do not split TGFb1 between the paragraphs. The section about circadian rhythm seems to be a
better fit in the Therapeutic strategies: Novel autophagy modulators section, as it is something to
further evaluate as a potential target.
4. Are there any genetic component as evidence of autophagy in COPD? For example: Chen et al.
2015; J Formos Med Assoc.

5. Should have a reference for the sentence regarding TGFb1 leads to accumulation of ECM. ECM
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5. Should have a reference for the sentence regarding TGFb1 leads to accumulation of ECM. ECM
could be abbreviate earlier in the article.
Is the topic of the review discussed comprehensively in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Yes
Is the review written in accessible language?
Yes
Are the conclusions drawn appropriate in the context of the current research literature?
Yes
Competing Interests: No competing interests were disclosed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Referee Report 10 April 2017

doi:10.5256/f1000research.12123.r21469
Eugene Roscioli
Royal Adelaide Hospital - Hanson Institute, University of Adelaide, Adelaide, SA, Australia
Summary statement
Kota et al. present an interesting and challenging subject for review – the interrelationship between
autophagy in the context of airway diseases that exhibit airway remodelling as a major pathological
feature. Challenging because we still have a lot to learn about both airway remodelling, and indeed the
diseases such as asthma and COPD that potentiate fibrotic airway changes, and further still the
contribution of increased or blocked autophagy as a driver, or parallel phenomena in this scenario. Overall
they provide a needed and good start to the discussion, that will no doubt pioneer further debate in these
areas off airway pathobiology. Hence, one leaves this review thinking about the link between fibrosis and
autophagy, but also, wondering what insight they gained to direct new lines of inquiry.
Major comments
As stated, this is by no means an easy literature review to compose. At first one would think this is due to
limited publication of such studies. However, a PubMed search using “Fibrosis[Title] and
Autophagy[Title]”, show there are 83 hits for this query. While the vast majority are not respiratory in
nature, it would be beneficial if Kota et al. could use mechanistic insights from other diseases to draw
hypothetical parallels with the situation that may be occurring in the airways, which they elude to in
paragraph 2 under the heading “Autophagy and fibrotic airway remodelling”, but little supposition is made
in regards to this thereafter. Indeed, this paragraph is possibly the only one which directly address the
subject matter stated by the title. Refreshingly however, they generously state new unpublished finding
(on three occasions) from their laboratory which provides insight for the reader and which have the
potential to direct further lines if understanding.
A current question for autophagy is: is it a block in autophagic flux leading to (or contributing to) the
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A current question for autophagy is: is it a block in autophagic flux leading to (or contributing to) the
cellular dyshomeostasis, or is autophagy increased because it is unable to manage the protracted/chronic
disease stressors? While Kota et al. touch upon this question for COPD, and correctly state that there is
significant conjecture with regards to this, subsequent discussion mainly lent to the increased autophagy
scenario, with an extended discussion with regards to cilia (ciliophagy). Indeed, we now know the
relationship between cilia and autophagy is a complex dual interaction whereby they foster each other’s
activity/generation rather than a one way situation where increased autophagy leads to the degradation of
cilia (Pampliega et al., 2016). Hence, some new insights/thoughts which could weigh into the autophagic
flux vs. increased autophagy debate would be welcomed.
Further, airway fibrosis occurs as a result of the chronic inflammation (in addition to e.g. altered smooth
muscle-epithelia interactions, between themselves and the inflammatory cells), while autophagy is known
to be an anti-inflammatory mechanism. Hence, beyond TGFβ, some insights into how the dysregulation of
autophagy leads to fibrosis driven by complex inflammatory changes at the airways would have been
informative.
Hence, while this review most certainly warrants publication, and marks yet another achievement for the
Oliver laboratory, the informed reader may ask for more than the start of the dialogue presented in this
particular review.

Minor comments
The manner of composition on occasions lacks maturity. For example, “ATG5 encodes a protein of 276
amino acids”, is not needed in a review article. The chronological presentation of concepts/studies,
should be forfeited to a style of writing that groups and discusses processes to illustrate a pattern of
phenomena that helps orient/inform the reader. Avoid using definite statements such as “clearly
indicates”, particularly in a review, and especially in areas where we have so much more to learn such as
is the case for chronic lung disease and autophagy. Finally, approximately one third of the 55 references
are review articles.
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